GE HealthCare $GEHC falls 9% after 2026 EPS guide cut to $4.80-$5.00
Original: GE HealthCare cuts annual profit forecast as inflation weighs on costs View original →
GE HealthCare $GEHC fell 9% in premarket trading after cutting its 2026 adjusted EPS outlook to $4.80-$5.00, even though first-quarter revenue rose 7.4% to $5.13 billion and topped estimates. The miss was not about demand. It was about margins, supplier friction, and an inflation bill that management now expects to last through the rest of the year.
The company's SEC-filed earnings release showed first-quarter adjusted EPS of $0.99, down from $1.01 a year earlier and below the $1.05 consensus cited by Reuters via Yahoo Finance. Diluted EPS fell to $0.85 from $1.23. Revenue reached $5.131 billion, while total orders rose 1.1% organically and backlog ended the quarter at $21.8 billion. Adjusted EBIT margin slipped to 13.5% from 15.0%, hit by a pharmaceutical-diagnostics supplier issue, tariffs, and weaker patient-care solutions performance.
Guidance is what reset the stock. GE HealthCare cut its full-year adjusted EBIT margin view to 15.4%-15.7% from 15.8%-16.1%, trimmed adjusted EPS to $4.80-$5.00 from $4.95-$5.15, and lowered free cash flow guidance to about $1.6 billion from $1.7 billion. CEO Peter Arduini said memory chips, oil, and freight costs rose sharply in the first quarter and are assumed to remain a headwind through 2026.
There were offsets. Imaging revenue rose 7.4% to $2.299 billion, pharmaceutical diagnostics revenue jumped 21.7% to $770 million, and the company kept its organic revenue growth outlook unchanged at 3.0%-4.0%. But investors usually punish medical-technology names when revenue holds up and margin guidance does not, because that combination tells the market pricing power is lagging cost pressure.
The next check is whether the supplier issue stays contained and whether price and cost actions can claw back more than half of the inflation hit, as management expects. If not, the quarter will be remembered less for a 7.4% top-line beat and more for the first evidence that 2026 healthcare equipment demand is arriving with much thinner operating leverage.
Not investment advice. Verify all figures with primary sources before acting.
Related Articles
Zscaler $ZS fell more than 21% premarket after Q3 revenue of $850.5M and adjusted EPS of $1.08 were offset by softer Q4 sales guidance and a lower FY26 free-cash-flow margin target.
Chow Tai Fook (1929.HK) rose 15% after FY2026 profit attributable to shareholders increased 52.2% to HK$9.004B. The company reported revenue of HK$94.398B, gross margin of 32.3% and operating profit margin of 20.0%.
Oracle $ORCL fell as much as 11% after Q4 results, with CNBC citing investor concern over a FY2027 funding plan of about $40B. Oracle’s release showed FY2026 free cash flow at negative $23.7B, RPO of $638B and Q4 non-GAAP EPS of $2.11.